Eli Lilly and Co. has entered a definitive agreement to acquire Prevail Therapeutics Inc. for a total consideration of up to $1.04 billion, payable subject to certain terms and conditions. Prevail is a biotechnology company developing potentially disease-modifying AAV9-based gene therapies for neurodegenerative diseases. The acquisition adds a new drug discovery and development modality, extending Lilly’s research efforts through the creation of a gene therapy program that will be anch...